These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 10199883

  • 1. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects.
    Rosenzweig EB, Kerstein D, Barst RJ.
    Circulation; 1999 Apr 13; 99(14):1858-65. PubMed ID: 10199883
    [Abstract] [Full Text] [Related]

  • 2. Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease.
    Thomas IC, Glassner-Kolmin C, Gomberg-Maitland M.
    Int J Cardiol; 2013 Oct 09; 168(4):4117-21. PubMed ID: 23890862
    [Abstract] [Full Text] [Related]

  • 3. [Effects of long-term treatment with prostacyclin on plasma adrenomedullin in patients with primary pulmonary hypertension].
    Nakayama T, Ishikita T, Matsuura H, Saji T.
    J Cardiol; 2001 Nov 09; 38(5):263-71. PubMed ID: 11729726
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure.
    Montalescot G, Drobinski G, Meurin P, Maclouf J, Sotirov I, Philippe F, Choussat R, Morin E, Thomas D.
    Am J Cardiol; 1998 Sep 15; 82(6):749-55. PubMed ID: 9761085
    [Abstract] [Full Text] [Related]

  • 7. Vasodilator therapy for primary pulmonary hypertension in children.
    Barst RJ, Maislin G, Fishman AP.
    Circulation; 1999 Mar 09; 99(9):1197-208. PubMed ID: 10069788
    [Abstract] [Full Text] [Related]

  • 8. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
    Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jöbsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA.
    Ann Intern Med; 2000 Mar 21; 132(6):425-34. PubMed ID: 10733441
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Short- and long-term effects of the new oral prostacyclin analogue, beraprost sodium, in patients with severe pulmonary hypertension].
    Saji T, Ozawa Y, Nakayama T, Matsuura H, Hashiguchi R, Matsuo N, Muto H, Yamazaki J, Morishita T, Saito T.
    J Cardiol; 1996 Apr 21; 27(4):197-205. PubMed ID: 8642506
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive ability and consequences on haemodynamics and gas exchange.
    Jolliet P, Bulpa P, Thorens JB, Ritz M, Chevrolet JC.
    Thorax; 1997 Apr 21; 52(4):369-72. PubMed ID: 9196521
    [Abstract] [Full Text] [Related]

  • 16. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.
    Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, Rainisio M, Simonneau G.
    J Am Coll Cardiol; 2002 Aug 21; 40(4):780-8. PubMed ID: 12204511
    [Abstract] [Full Text] [Related]

  • 17. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension.
    Wax D, Garofano R, Barst RJ.
    Chest; 1999 Oct 21; 116(4):914-20. PubMed ID: 10531153
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.
    McLaughlin VV, Shillington A, Rich S.
    Circulation; 2002 Sep 17; 106(12):1477-82. PubMed ID: 12234951
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.